Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 and mRNA-1443 CMV vaccines in healthy adults
NCT03382405Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in cytomegalovirus infection (CMV) comparing mRNA-1647, mRNA-1443 and Placebo (3 arms). Primary endpoints: Frequency of solicited adverse events, Frequency of unsolicited adverse events and 2 more. Started Nov 2017; status: completed.
02
Drugs
mRNA-1647mRNA-1443
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03382405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382405.